A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD)

Size: px
Start display at page:

Download "A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD)"

Transcription

1 Eur Child Adolesc Psychiatry (2009) 18: DOI /s z ORIGINAL CONTRIBUTION Javad Alaghband-Rad Mitra Hakimshooshtary A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD) Accepted: 16 January 2007 Published online: 3 February 2009 J. Alaghband-Rad, MD (&) Dalhousie University 5217 Morris Street Halifax, NS B3J 1B7 Canada and Tehran University of Medical Sciences Tehran, Iran Fax: rad@dal.cd M. Hakimshooshtary, MD Iran University of Medical Sciences Tehran, Iran j Abstract Objective Several controlled trials have demonstrated the efficacy and safety of Fluoxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), but there is no controlled study on the effectiveness of Citalopram in this group. This report describes the use of Citalopram in comparison with Fluoxetine in childhood-onset OCD. Method This study is a randomized, double blind, fixeddoes (20mg) trial of Fluoxetine versus Citalopram in 29 children and adolescents (17 boys and 12 girls) with OCD, aged 7 18 years (mean 13.8 and SD 3.05). The length of study was 6 weeks. Obsessive-Compulsive symptom severity was measured by Yale Brown Obsessive-Compulsive Scale (CY-BOCS) and Clinician s Global Impression Scale (CGI). DICA (Diagnostic Interview of Children and Adolescents) was used to diagnose the psychiatric disorders. Results Each group showed significant improvement over the baseline as measured by the CY-BOCS (p < 0.01) but not by CGI (p = NS). The Comparison between two groups showed no significant differences in efficacy and safety of the drugs. Most common adverse effects were headache for Citalopram and tremor for Fluoxetine. Conclusion The results suggest that Citalopram is as safe and effective as Fluoxetine for children and adolescents with OCD. Further studies are needed to replicate our findings. j Key words Fluoxetine Citalopram children and obsessive-compulsive disorder Introduction Accumulating clinical and epidemiological data indicate that OCD is more common than previously recognized in both children and adults; recent estimates of prevalence range from 0.5% to 3.0% [1, 7]. Children and adolescents evaluated in clinical settings often have symptoms of severity to warrant treatment [4, 8, 12, 15], which may include behavioral therapy [10] and/or medication particularly SSRIs [3]. Controlled clinical trials with Fluoxetine indicate that it is effective in reducing obsessive-compulsive symptom severity in children and adolescents [2, 12, 13], but there are no controlled trial to support the use of Citalopram in children and adolescents with OCD. Citalopram is reported to be effective in early-onset Depression [8]. The purpose of this study was to compare the efficacy and side effects profile of these two drugs in children and adolescents with OCD. Assessment included severity ratings of obsessive-compulsive symptoms, functional impairment, presence of comorbidities and side effects. ECAP 634

2 132 European Child & Adolescent Psychiatry (2009) Vol. 18, No. 3 Ó Steinkopff Verlag 2009 Method From May 1999 through September 2002, 29 children and adolescents were evaluated in the child and adolescent psychiatry outpatient clinic at Roozbeh hospital, Tehran. To be included in the study, subjects had to meet DSM-IV criteria for OCD made by an experienced child psychiatrist (JA or MS), be between the ages of 8 years and 17 years, have at least moderate symptoms of OCD as measured on the Clinical Global Impression Severity Scale (CGI-S), and have written informed parental consent and assent in children old enough to understand the purpose of the study. Children with date table organic brain disorder; those with a significant medical condition or those currently receiving SSRI for OCD were excluded from the study. j Design After initial clinical evaluation, consenting subjects were randomly assigned to start with either Fluoxetine 20 mg/day or Citalopram 20 mg/day. The doubleblind treatment period lasted for 6 weeks with outcome and safety assessments done every 3 weeks. Compliance was monitored by pill counts. A 3- week supply of medication was provided at each visit, and parents were instructed to return all unused medication at each scheduled visit. No additional psychoactive medications were administered during the study. No subjects were receiving special educational programs or behavioral treatments. Interviewer conducted a semi structural interview and administered the symptom severity ratings, functional impairment and side effects instruments (Table 1). j Procedures Screening and baseline assessment In the screening visit, subjects received a thorough psychiatric, medical and neurological examination by an experienced child psychiatrist (JA or MS). This included a structured diagnostic interview, DICA [5, 6], to evaluate for exclusionary comorbid conditions. Table 1 Study design Measures Baseline 3 weeks 6 weeks Baseline assessment measures X CY-BOCS X X X CGI-OCD X X X DICA X Side effect ratings X X X Once deemed eligible for the study, an overall clinician rating of obsessive-compulsive symptoms CGI-S and functional impairment Children s Global Assessment Scale were administered. j Outcome measures The children s Yale Brown obsessive-compulsive Scale (CYBOCS) is a clinician-rated instrument for the measurement of obsessive-compulsive symptom severity in children with demonstrated reliability and validity (18). Obsessions and compulsions are on 5 separate scales yielding three summary s; Obsessive (0 20), Compulsions (0 20) and a Total (0 40). The CYBOCS was administrated by an experienced clinician (MS) repeated at weeks 3 and 6. The Clinical Global Impression-Improvement (CGI-I) compares current severity to baseline. A 1 or 2 corresponds with Very Much Improved and Much Improved; 3 denotes minimal change and 4 represents no change. Scores above 4 are used to indicate deterioration such that 5 equals Minimally Worse and 6 or 7 correspond with Much Worse or Very Much Worse. The CGI-I rated by the same clinician who administered the CYBOCS, was repeated at weeks 3 and 6. Side effects ratings: all positive Findings elicited during the interview were recorded. j Statistical analyses Student s t-test was used to compare Fluoxetine and Citalopram groups at baseline on all clinical symptoms as well as demographic and medical variables. Analysis of covariance (ANCOVA) was used to test for change on each clinical measure between baseline and 3-week s within each treatment group and then between 3-week s and 6-week s within each treatment group. Baseline versus six weeks change s for each subject was then compared across treatment groups for each clinical variable using student s t-test. All t- test were 2-tailed. Results During the study period, 29 children (17 boys and 12 girls) who met criteria for OCD were evaluated and entered the study. None of them had received previous treatment for OCD. There were 15 subjects in the Fluoxetine treatment group and 14 subjects in the Citalopram group. Twenty-four of the 29 subjects completed the 6 weeks trial. Four subjects dropped out after 3 weeks of treatment. The other patient was

3 J. Alaghband-Rad and M. Hakimshooshtary 133 Citalopram and OCD Table 2 Overall clinical response to fluoxetine treatment Variable Pre-treatment At third week Post-treatment Total CY-BOCS <0.001 CGI >0.001 p CY-BOCS CY-BOCS CGI f CGI p CY CGI excluded because of occurring hypomanic episode. Data from 24 to 29 subjects who began the study were used in the analyses (Table 2). For all analyses we used the primary outcome measures, the CY-BOCS total and CGI-OCD (Figs. 1 and 2). There were no statistically significant differences between Fluoxetine and Citalopram groups across symptom-severity ratings, demographic characteristics or psychiatric comorbidities. obsessive-compulsive symptom severity was moderately high with an overall mean of 26.9 ± for the whole group. The mean CGI of 51.5 ± showed that as a group, these patients were substantially impaired. DICA indicated a high degree of comorbidities. The mean CGI indicated a lower degree of functional impairment in comparison with the clinically observed obsessive-compulsive symptoms. This may reflect perfectionistic traits in patients with OCD that prevents them from severe functional decline. j Efficacy: first three weeks third week Fig. 1 CGI changes during the 6 weeks of treatment sixth week After 3 weeks of treatment, obsessive-compulsive symptom severity for both groups decreased equally, as measured by CY-BOCS total s. On the CY- BOCS, s decreased for both obsessions and compulsions. CGI s didn t change significantly from baseline in both groups, however. 0 j Efficacy: third through sixth weeks At sixth week of treatment, obsessive-compulsive symptom severity for both groups decreased equally, as measured by CY-BOCS total s. On the CY- BOCS, s decreased for both obsessions and compulsions (p < 0.01). CGI didn t change significantly from baseline in both groups (p = NS). j Side effects The most frequently reported side effects were: Headache 1 (3.4%), Tremor 2 (6.8%), Insomnia 1 (3.4%), Hypomanic Episode 1 (3.4%) for fluoxetine. Headache 1 (3.4%), Hypomanic Episode 1 (3.4%) for citalopram. The frequency of comorbid current psychiatric diagnoses, made by consensus of the same clinicians using DICA [9, 10], was as it follows: Tic disorder: 7 (21.28%), Oppositional Defiant Disorder: 7 (21.28%), Mood disorder: 6 (20.4%), Phobia: 4 (13.6%), Attention-Deficit Hyperactivity Disorder: 3 (10.2%), Generalized Anxiety Disorder: 3 (10.2%), Trichotillomania: 1 (3.4%). It should be noted that in 66% of cases, OCD was reported in the families as well. Discussion third week Fig. 2 CY-BOCS changes during the first 6 weeks of treatment sixth week The findings of this study suggest that Citalopram is as safe and effective as Fluoxetine for short-term

4 134 European Child & Adolescent Psychiatry (2009) Vol. 18, No. 3 Ó Steinkopff Verlag 2009 Table 3 Overall clinical response to citalopram treatment Variable Pre-treatment At third week Post-treatment Total CY-BOCS <0.001 CGI >0.01 treatment of OCD in children and adolescents. In line with other studies, we also found that 73% of the patients had comorbid disorder especially tic disorder, ODD, ADHD and mood disorder. In 66% of cases, OCD was reported in the families as well. The medication side effects were not significant. Citalopram had to be discontinued in one subject who developed manic episode. Decreases in mean obsessive-compulsive symptom severity; averaged 56.1% depending on the assessment instrument used, and were seen after six weeks of treatment. Four subjects dropped out of the study because of noncompliance. We observed lower degree of functional impairment while high degrees of obsessive-compulsive symptoms were rated. It might be due to perfectionist traits that prevent them from severe functional decline. This is in line with previous studies. Taken together, these findings suggest that both drugs are equally effective and safe. However, larger number of children with OCD will need to be studied in order to definitively establish efficacy and safety of Citalopram. The degree of symptomatic improvement during Citalopram treatment observed in this study is comparable with those observed in trials of Fluoxetine in children and adolescents (Table 3). In a 20-week, double blind, crossover trial of Fluoxetine and placebo involving 14 subjects [11], obsessive-compulsive symptom severity decreased 44% across CGI-OCD during Fluoxetine treatment. In a 13-week, double blind, placebo-controlled study of Fluoxetine involving 103 subjects [2], obsessive-compulsive symptom P showed greater improvement, as assessed by CY- BOCS (p = 0.026). Most of the observed side effects, such as insomnia, headache, and tremor, were expected, on the basis of our earlier experience with Citalopram in open-label trials [9, 16]. Citalopram had to be discontinued in only one subject because of occurring hypomanic episode. j Clinical Implications OCD can create emotional distress and functional impairment. There is no controlled trial about prescribing citalopram in children and adolescents. Investigation into the use of Citalopram is a necessity. Citalopram has a shorter half-life than fluoxetine and can be effective in some special cases [14]. It also has few side effects. As SSRIs have increasingly become the first choice treatment of OCD in children and adolescents, it is very important to have efficacy and safety data on as many of them as possible. This would help us to handle the wide individual differences in drug metabolism. There might also be subgroups of OCD patients who respond differentially to various SSRIs. Therefore, further investigation into the use of Citalopram is needed. j Limitations The most important limitation of our study includes the small sample size. Also, our patients admitted at a tertiary referral center are more likely to present with psychiatric comorbidities than patients who do not seek treatment. The other limitation is comparing two active treatments without considering placebo group. Moreover, we have used only one OCD severity measure before giving the medications. j Acknowledgment The authors thankfully acknowledge the helpful and rewarding comments made by Dr. Larry Scahill, Yale child study center (New Haven, USA). References 1. Flament MF, Whitaker A, rapport JL, Davies M, Berg CZ, Kalikow K (1998) Obsessive Compulsive Disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27: Geller DA, Hoog SL, Heilligensein JH, Ricardi K, Tamura R, Kluszyski S, Jacobson JG (2001) Fluoxetine treatment of obsessive compulsive disorder in children and adolescents, a placebocontrolled clinical trial. J Am Acad Child Adolesc Psychiatry 40: Grados M, Scahill L, Riddle MA (1999) Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Child Adolesc Psychiatry Clin N Am 8(3): , Review 4. Hanna GL, Yuwiler A, Coates JK (1995) Whole blood serotonin and disruptive behaviors in juvenile obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34(1):28 35

5 J. Alaghband-Rad and M. Hakimshooshtary 135 Citalopram and OCD 5. Herjanic B, campbell W (1977) Differentiating psychiatrically disturbed children on the basis of a structured interview. J Abnorm Child Psychol 5: Herjanic B, Reich W (1982) Development of a structured psychiatric interview for children: agreement between child and parent on individual symptoms. J Abnormal Child Psychol 10: Karno M, Golding JM, Sorenson SB, Burnam MA (1988) The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45(12): Leonard HL, Swedo SE, Lenane MC, Rettew DC, Hamburger SD, Bartko JJ, Rapoport JL (1993) A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 50(6): Mukaddes NM, Abali O, Kaynak N (2003) Citalopram treatment of children and adolescents with obsessivecompulsive disorder: a preliminary report. Psychiatry Clin Neurosci 57: Piacentini J (1999) Cognitive behavioral therapy of childhood OCD. Child Adolesc Psychiatry Clin N Am 8(3): , Review 11. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI (1992) Double-blind, crossover trial of Fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31: Riddle MA, Scahill L, King R, Hardin MT, Towbin KE, Ort SI (1990) Obsessive compulsive disorder in children and adolescents: phenomenology and family history. J Am Acad Child Adolesc Psychiatry 29: Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF (1997) Children s Yale Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36(6): Shirazi E, Alaghband-rad J (2005) An open trial of citalopram in children and adolescents with depression. J Child Adolesc Psychopharmacol 15: Swedo SE, rapoport JL, Leonard H, Lenin M, Cheslow D (1989) Obsessivecompulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 46: Thomsen PH (1997) Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 7:

Interrater reliability and clinical efficacy of Children s Yale-Brown Obsessive-Compulsive Scale in an outpatient setting

Interrater reliability and clinical efficacy of Children s Yale-Brown Obsessive-Compulsive Scale in an outpatient setting Comprehensive Psychiatry 47 (2006) 48 53 www.elsevier.com/locate/comppsych Interrater reliability and clinical efficacy of Children s Yale-Brown Obsessive-Compulsive Scale in an outpatient setting A. Guldeniz

More information

Disentangling chronological age from age of onset in children and adolescents with obsessive compulsive disorder

Disentangling chronological age from age of onset in children and adolescents with obsessive compulsive disorder International Journal of Neuropsychopharmacology (2001), 4, 169 178. Copyright 2001 CINP Disentangling chronological age from age of onset in children and adolescents with obsessive compulsive disorder

More information

Fluoxetine, a specific serotonin uptake inhibitor, is approved for use as an antidepressant in adults and

Fluoxetine, a specific serotonin uptake inhibitor, is approved for use as an antidepressant in adults and JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY Volume, Number, 99/99 Mary Ann Liebert, Inc., Publishers Behavioral Side Effects of Fluoxetine in Children and Adolescents MARK A. RIDDLE, M.D., ROBERT

More information

Cognitive Behavioral Therapy Plus Motivational Interviewing Improves Outcome for Pediatric Obsessive Compulsive Disorder: A Preliminary Study

Cognitive Behavioral Therapy Plus Motivational Interviewing Improves Outcome for Pediatric Obsessive Compulsive Disorder: A Preliminary Study Cognitive Behaviour Therapy Vol 39, No 1, pp. 24 27, 2010 Cognitive Behavioral Therapy Plus Motivational Interviewing Improves Outcome for Pediatric Obsessive Compulsive Disorder: A Preliminary Study Lisa

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,

More information

Background Paper: Obsessive Compulsive Disorder. Kristen Thomas. University of Pittsburgh

Background Paper: Obsessive Compulsive Disorder. Kristen Thomas. University of Pittsburgh Background Paper: Obsessive Compulsive Disorder Kristen Thomas University of Pittsburgh December 2011 2 According to the DSM-IV, obsessive compulsive disorder (OCD) will be diagnosed when the child displays

More information

Obsessive-compulsive disorder (OCD) is a

Obsessive-compulsive disorder (OCD) is a Obsessive-Compulsive Scale of the Child Behavior Checklist: Specificity, Sensitivity, and Predictive Power Elliot C. Nelson, MD*; Gregory L. Hanna, MD ; James J. Hudziak, MD ; Kelly N. Botteron, MD*; Andrew

More information

Antidepressant does not relieve repetitive behaviors

Antidepressant does not relieve repetitive behaviors NEWS Antidepressant does not relieve repetitive behaviors BY KELLY RAE CHI 16 JUNE 2009 1 / 5 Bitter pill: Negative results from clinical trials of two antidepressants, Celexa and Prozac, challenge the

More information

Prevalence and Pattern of Psychiatric Disorders in School Going Adolescents

Prevalence and Pattern of Psychiatric Disorders in School Going Adolescents The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 4, Issue 3, No. 100, DIP 18.01.074/20170403 ISBN: 978-1-387-00243-6 http://www.ijip.in April-June, 2017 Prevalence

More information

Reliability and validity of the Child Behavior Checklist Obsessive-Compulsive Scale

Reliability and validity of the Child Behavior Checklist Obsessive-Compulsive Scale Anxiety Disorders 20 (2006) 473 485 Reliability and validity of the Child Behavior Checklist Obsessive-Compulsive Scale Eric A. Storch a,b, *, Tanya K. Murphy b, Daniel M. Bagner c, Natalie B. Johns b,

More information

Final Report of Activity February 21 st, 2006 to April 30 th, 2006 CHEO Grant 052

Final Report of Activity February 21 st, 2006 to April 30 th, 2006 CHEO Grant 052 Final Report of Activity February 21 st, 2006 to April 30 th, 2006 CHEO Grant 052 1- Title of Study: The prevalence of neuropsychiatric disorders in children and adolescents on an inpatient treatment unit:

More information

for anxious and avoidant behaviors.

for anxious and avoidant behaviors. Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence

More information

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

5 COMMON QUESTIONS WHEN TREATING DEPRESSION 5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective

More information

정서적불안정을동반한 PANDAS 1 예

정서적불안정을동반한 PANDAS 1 예 KISEP Case Report J Korean Neuropsychiatr Assoc Vol 43, No 3 1 예 전남대학교병원정신과 양종철 A Case of PANDAS with Emotional Lability Jong-Chul Yang, MD, PhD Department of Psychiatry, Cheonnam National University Hospital,

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBX

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBX CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-

More information

A prospective study of anxiety disorders in children

A prospective study of anxiety disorders in children A prospective study of anxiety disorders in children Last, Cynthia; Perrin, Sean; Hersen, Michel; Kazdin, Alan Published in: Journal of the American Academy of Child and Adolescent Psychiatry DOI: 10.1097/00004583-199611000-00019

More information

Childhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities

Childhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities Childhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities By: Dr. Ehsane M. Gad M.B.B.Ch CABMSPsych. D.P.P Post-Fellow Aus. Consultant Child Psychiatry Childhood ADHD and emergence

More information

Further Psychometric Examination of the Tourette s Disorder Scales

Further Psychometric Examination of the Tourette s Disorder Scales Child Psychiatry Hum Dev (2007) 38:89 98 DOI 10.1007/s10578-006-0043-4 ORIGINAL PAPER Further Psychometric Examination of the Tourette s Disorder Scales Eric A. Storch Æ Lisa J. Merlo Æ Heather Lehmkuhl

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

Psychopharmacology of Autism Spectrum Disorder

Psychopharmacology of Autism Spectrum Disorder Psychopharmacology of Autism Spectrum Disorder Christopher J. McDougle, MD Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral Hospital

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium escitalopram, 5mg, 10mg, and 20mg tablets and 10mg/ml oral drops (Cipralex) No. (406/07) Lundbeck Ltd 7 September 2007 The Scottish Medicines Consortium has completed its

More information

PANS-PANDAS An Update on Research and Clinical Management

PANS-PANDAS An Update on Research and Clinical Management PANS-PANDAS An Update on Research and Clinical Management Kyle Williams, MD PhD Director, Pediatric Neuropsychiatry and Immunology Program Massachusetts General Hospital Clinical Case-PANDAS 10 y.o. male

More information

Psychopharmacology for Non-MDs - Dr. Suzanne Dieter. March 10, 2017 PEDIATRIC PSYCHOPHARMACOLOGY FOR NON-MDS LEARNING OBJECTIVES

Psychopharmacology for Non-MDs - Dr. Suzanne Dieter. March 10, 2017 PEDIATRIC PSYCHOPHARMACOLOGY FOR NON-MDS LEARNING OBJECTIVES LEARNING OBJECTIVES PEDIATRIC PSYCHOPHARMACOLOGY FOR NON-MDS, MD New York, NY Member, American Academy of Child and Adolescent Psychiatry Understand the role a child psychiatrist can play as part of a

More information

A 7 year follow-up of children and adolescents with obsessive-compulsive disorder. An analysis of predictive factors in a clinical prospective study

A 7 year follow-up of children and adolescents with obsessive-compulsive disorder. An analysis of predictive factors in a clinical prospective study Eur. J. Psychiat. Vol. 28, N. 3, (183-193) 2014 Keywords: Children and Adolescents; OCD; Obsessive compulsive disorder; Follow-up study; Pre - dictive factors. A 7 year follow-up of children and adolescents

More information

Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder

Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder in Children and Adolescents With Obsessive-Compulsive Disorder A Multicenter Randomized Controlled Trial John S. March, MD, MPH; Joseph Biederman, MD; Robert Wolkow, MD; Allan Safferman, MD; Jack Mardekian,

More information

Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder

Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder THE JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY Journal of Child Psychology and Psychiatry 49:5 (2008), pp 489 498 doi:10.1111/j.1469-7610.2007.01875.x Meta-analysis of randomized, controlled treatment

More information

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

Pharmacological interventions for children with Disruptive Behaviour Disorders or Conduct Disorder or Oppositional Defiant Disorder

Pharmacological interventions for children with Disruptive Behaviour Disorders or Conduct Disorder or Oppositional Defiant Disorder updated 2012 Pharmacological interventions for children with Disruptive Behaviour Disorders or Conduct Disorder or Oppositional Defiant Disorder Q8: What is the effectiveness, safety and role of pharmacological

More information

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive

More information

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive

More information

6/22/2012. Co-morbidity - when two or more conditions occur together. The two conditions may or may not be causally related.

6/22/2012. Co-morbidity - when two or more conditions occur together. The two conditions may or may not be causally related. Autism Spectrum Disorders and Co-existing Mental Health Issues By Dr. Karen Berkman Objective To present an overview of common psychiatric conditions that occur in persons with autism spectrum disorders

More information

Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ

Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center

More information

Diagnosing Psychological Disorders

Diagnosing Psychological Disorders Diagnosing Psychological Disorders Chapter 2 Diagnosis and Treatment The Client and Clinician Client: The person Clinician: The person Psychiatrists Receive specialized advanced training in diagnosing

More information

Medications in Autism: What We Know and Don't Know

Medications in Autism: What We Know and Don't Know Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental

More information

Prospective assessment of treatment use by patients with personality disorders

Prospective assessment of treatment use by patients with personality disorders Wesleyan University From the SelectedWorks of Charles A. Sanislow, Ph.D. February, 2006 Prospective assessment of treatment use by Donna S. Bender Andrew E. Skodol Maria E. Pagano Ingrid R. Dyck Carlos

More information

An Update on the Treatment of Obsessive Compulsive Disorder In Children and Adolescents

An Update on the Treatment of Obsessive Compulsive Disorder In Children and Adolescents An Update on the Treatment of Obsessive Compulsive Disorder In Children and Adolescents Kyle Williams, MD, PhD Director, Pediatric Neuropsychiatry and Immunology Program Massachusetts General Hospital

More information

Advocating for people with mental health needs and developmental disability GLOSSARY

Advocating for people with mental health needs and developmental disability GLOSSARY Advocating for people with mental health needs and developmental disability GLOSSARY Accrued deficits: The delays or lack of development in emotional, social, academic, or behavioral skills that a child

More information

Obsessive/Compulsive Disorder

Obsessive/Compulsive Disorder Obsessive/Compulsive Disorder An Overview of the Diagnosis, Symptoms, Assessment and Treatment in Behavioral Health Martin J. Harrington M.D., Staff Child/Adolescent Psychiatrist Children s Hospital and

More information

Is Lisdexamfetamine Dimesylate Safe and Effective in Reducing ADHD Symptoms?

Is Lisdexamfetamine Dimesylate Safe and Effective in Reducing ADHD Symptoms? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Lisdexamfetamine Dimesylate Safe

More information

Tourette s Disorder and Tics Child and Adolescent Psychopharmacology

Tourette s Disorder and Tics Child and Adolescent Psychopharmacology Tourette s Disorder and Tics Child and Adolescent Psychopharmacology March 3, 2018 Barbara J. Coffey, MD, MS Division Chief, Child and Adolescent Psychiatry Professor, Department of Psychiatry and Behavioral

More information

Prevalence of comorbidities in children with attention deficit and hyperactivity disorder at Lady Ridgeway Hospital for Children, Sri Lanka

Prevalence of comorbidities in children with attention deficit and hyperactivity disorder at Lady Ridgeway Hospital for Children, Sri Lanka Original Articles Prevalence of comorbidities in children with attention deficit and hyperactivity disorder at Lady Ridgeway Hospital for Children, Sri Lanka *G S Wijetunge 1, J C Dayasena 2, I C Kulathilake

More information

EPIDEMIOLOGIC DATA SUGGEST

EPIDEMIOLOGIC DATA SUGGEST ORIGINAL CONTRIBUTION, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive Disorder The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial The Pediatric

More information

Are Behavioural Disorders a separate nosological category of disorders?

Are Behavioural Disorders a separate nosological category of disorders? 249 Review Article Are Behavioural Disorders a separate nosological category of disorders? Shrirang Bakhle 1 1 Consulting Physician, Mumbai. E-mail ss.bakhle@gmail.com ABSTRACT The term Behavioural Disorders

More information

Impact of Comorbidity on Cognitive-Behavioral Therapy Response in Pediatric Obsessive-Compulsive Disorder

Impact of Comorbidity on Cognitive-Behavioral Therapy Response in Pediatric Obsessive-Compulsive Disorder Impact of Comorbidity on Cognitive-Behavioral Therapy Response in Pediatric Obsessive-Compulsive Disorder ERIC A. STORCH, PH.D., LISA J. MERLO, PH.D., MICHAEL J. LARSON, M.S., GARY R. GEFFKEN, PH.D., HEATHER

More information

D I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.

D I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment. Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor

More information

Identifying and Treating Anxiety Disorders

Identifying and Treating Anxiety Disorders June 2015 NEWS Identifying and Treating Anxiety Disorders From being afraid of the dark to getting nervous before major exams, some anxiety is a normal part of childhood and adolescence. But when worries

More information

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives

More information

Randomised controlled trial of parent-enhanced CBT compared with individual CBT for. Obsessive Compulsive Disorder in young people. Shirley A Reynolds

Randomised controlled trial of parent-enhanced CBT compared with individual CBT for. Obsessive Compulsive Disorder in young people. Shirley A Reynolds Randomised controlled trial of parent-enhanced CBT compared with individual CBT for Obsessive Compulsive Disorder in young people Shirley A Reynolds Charlie Waller Institute, University of Reading Sarah

More information

The Reliability and Validity of Kiddie- the Schedule for Affective Disorders and. Schizophrenia - Present and Life-time Version - Persian Version

The Reliability and Validity of Kiddie- the Schedule for Affective Disorders and. Schizophrenia - Present and Life-time Version - Persian Version Child and Adolescent Mental Health Volume **, No. *, 2009, pp. ** ** doi: 10.1111/j.1475-3588.2008.00518.x The Reliability and Validity of Kiddie- Schedule for Affective Disorders and Schizophrenia - Present

More information

PANDAS/PANS DIAGNOSIS AND TREATMENT. Sophie Fowler FNP-BC

PANDAS/PANS DIAGNOSIS AND TREATMENT. Sophie Fowler FNP-BC PANDAS/PANS DIAGNOSIS AND TREATMENT Sophie Fowler FNP-BC OBJECTIVES 1. Working knowledge of PANDAS/PANS 2. Awareness of predisposition factors 3. Awareness of common misdiagnoses 4. Differences in presentation

More information

Correlates of comorbid anxiety and externalizing disorders in childhood obsessive compulsive disorder

Correlates of comorbid anxiety and externalizing disorders in childhood obsessive compulsive disorder Eur Child Adolesc Psychiatry (2010) 19:637 645 DOI 10.1007/s00787-010-0101-0 ORIGINAL CONTRIBUTION Correlates of comorbid anxiety and externalizing disorders in childhood obsessive compulsive disorder

More information

Key Messages. Around 20% of children and adolescents are estimated to have mental health disorders or problems

Key Messages. Around 20% of children and adolescents are estimated to have mental health disorders or problems Key Messages Around 20% of children and adolescents are estimated to have mental health disorders or problems In a young person presenting with mental health problems, assessment of suicide risk should

More information

OBSESSIVE-COMPULSIVE DISORder

OBSESSIVE-COMPULSIVE DISORder ORIGINAL CONTRIBUTION Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial Martin

More information

The PANDAS Subtype of Childhood-onset Obsessive Compulsive Disorder: Continued Controversy? Or Case Closed? PDN

The PANDAS Subtype of Childhood-onset Obsessive Compulsive Disorder: Continued Controversy? Or Case Closed? PDN The PANDAS Subtype of Childhood-onset Obsessive Compulsive Disorder: Continued Controversy? Or Case Closed? PDN The Controversy Begins The Controversy Continues What is PANDAS? Outline of Talk Historical

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical

More information

Disclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017

Disclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017 Psychopharmacology of Pediatric Anxiety and Depression Susan Sharp, DO Clinical Assistant Professor of Child and Adolescent Psychiatry Kansas University Medical Center The Children's Mercy Hospital, 2017

More information

J. Indian Assoc. Child Adolesc. Ment. Health 2012; 8(1):1-5. Editorial

J. Indian Assoc. Child Adolesc. Ment. Health 2012; 8(1):1-5. Editorial 1 J. Indian Assoc. Child Adolesc. Ment. Health 2012; 8(1):1-5 Editorial Controversies in Paediatric Bipolar Disorder Vivek Agarwal 1, Sivakumar T 2 1.Editor JIACAM & Associate Professor, Department of

More information

Ben Assan Senior Clinician and family Therapist Austin CAMHS, Melbourne.

Ben Assan Senior Clinician and family Therapist Austin CAMHS, Melbourne. Ben Assan Senior Clinician and family Therapist Austin CAMHS, Melbourne. Introduction OCD in adolescents Current treatment models Review of cases Rethink of current treatment models Current treatment plus

More information

Suitable dose and duration of fluvoxamine administration to treat depression

Suitable dose and duration of fluvoxamine administration to treat depression PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original

More information

EFFECTS OF MICRONUTRIENTS ON ANXIETY AND STRESS IN CHILDREN

EFFECTS OF MICRONUTRIENTS ON ANXIETY AND STRESS IN CHILDREN EFFECTS OF MICRONUTRIENTS ON ANXIETY AND STRESS IN CHILDREN Ellen J. Sole, Julia J. Rucklidge, & Neville M Blampied. University of Canterbury Christchurch, New Zealand World Congress of Cognitive-Behavioural

More information

PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE

PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE Introduction and General Principles April 2017 Adapted for New Mexico from with permission from the Texas Department

More information

An Industry- Biased Record

An Industry- Biased Record SSRI Use In Children: An Industry- Biased Record February 2004 By Merrill Goozner and Jeff DelViscio Tel: (202) 332-9110 Fax: (202) 265-4954 www.cspinet.org Suite 300 1875 Connecticut Avenue, NW Washington,

More information

Sensory Gating Scales and Premonitory Urges in Tourette Syndrome

Sensory Gating Scales and Premonitory Urges in Tourette Syndrome Short Communication TheScientificWorldJOURNAL (2011) 11, 736 741 ISSN 1537-744X; DOI 10.1100/tsw.2011.57 Sensory Gating Scales and Premonitory Urges in Tourette Syndrome Ashley N. Sutherland Owens 1, Euripedes

More information

Impact of Comorbidities on Self-Esteem of Children with Attention Deficit Hyperactivity Disorder

Impact of Comorbidities on Self-Esteem of Children with Attention Deficit Hyperactivity Disorder The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 3, Issue 3, No.1, DIP: 18.01.011/20160303 ISBN: 978-1-365-03416-9 http://www.ijip.in April - June, 2016 Impact

More information

Psychiatric Disorders and Treatments in Children with VCFS

Psychiatric Disorders and Treatments in Children with VCFS Psychiatric Disorders in VCFS at Different Age Groups Psychiatric Disorders and Treatments in Children with VCFS Prof. Doron Gothelf, M.D. The Behavioral Neurogenetics Center Edmond & Lily Safra Children

More information

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) Brittany Andry, MD PGY III Pediatric Resident LSUHSC

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) Brittany Andry, MD PGY III Pediatric Resident LSUHSC Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) Brittany Andry, MD PGY III Pediatric Resident LSUHSC Objectives Learn the diagnostic criteria of Pediatric Autoimmune

More information

Summary of the Recent Literature on the Treatment of Obsessive Compulsive Disorder in Children and Adolescents 6-17 Years

Summary of the Recent Literature on the Treatment of Obsessive Compulsive Disorder in Children and Adolescents 6-17 Years Summary of the Recent Literature on the Treatment of Obsessive Compulsive Disorder in Children and Adolescents 6-17 Years Tanya Murphy, MD., MS* The proposed lifetime prevalence of obsessive compulsive

More information

STUDY OF PSYCHIATRIC DISORDERS IN CHILDREN AND ADOLESCENTS TO INTRODUCE A NEWER CLASSIFICATION SYSTEM

STUDY OF PSYCHIATRIC DISORDERS IN CHILDREN AND ADOLESCENTS TO INTRODUCE A NEWER CLASSIFICATION SYSTEM STUDY OF PSYCHIATRIC DISORDERS IN CHILDREN AND ADOLESCENTS TO INTRODUCE A NEWER CLASSIFICATION SYSTEM Shyamanta Das 1, Dipesh Bhagabati 2, Puneet Mathur 3, Angshuman Kalita 4, Nabanita Sengupta 5, Sakhee

More information

Bipolar Disorder in Youth

Bipolar Disorder in Youth Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset

More information

Disruptive mood dysregulation disorder (DMDD) a

Disruptive mood dysregulation disorder (DMDD) a Disruptive mood dysregulation disorder: A better understanding Recognizing key differences in DMDD can help distinguish it from similar pediatric disorders Disruptive mood dysregulation disorder (DMDD)

More information

A Study on Patients with Obsessive Compulsive Disorder from Urban, Semi-Rural and Rural Areas of West Bengal

A Study on Patients with Obsessive Compulsive Disorder from Urban, Semi-Rural and Rural Areas of West Bengal The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 3, Issue 4, No. 60, DIP: 18.01.086/20160304 ISBN: 978-1-365-26308-8 http://www.ijip.in July-September, 2016

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options

Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between

More information

Study Center(s): The study was conducted at 39 study sites in Japan.

Study Center(s): The study was conducted at 39 study sites in Japan. SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01

More information

A Systematic Chart Review of the Nature of Psychiatric Adverse Events in Children and Adolescents Treated with Selective Serotonin Reuptake Inhibitors

A Systematic Chart Review of the Nature of Psychiatric Adverse Events in Children and Adolescents Treated with Selective Serotonin Reuptake Inhibitors JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY Volume 13, Number 2, 2003 Mary Ann Liebert, Inc. Pp. 143 152 A Systematic Chart Review of the Nature of Psychiatric Adverse Events in Children and Adolescents

More information

PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER Attention-Deficit / Hyperactivity Disorder (ADHD). (2017, August 31). Retrieved April 06,

More information

Overview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders

Overview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders 1 Learning Objectives 1. Providers will become familiar with methods of screening for depression and anxiety. 2. Providers will become more comfortable with diagnosis and management of these common pediatric

More information

An Overview of Anxiety and Mood Disorders in Youth

An Overview of Anxiety and Mood Disorders in Youth An Overview of Anxiety and Mood Disorders in Youth Mary Kay Nixon MD FRCPC Clinical Associate Professor, UBC Affliliate Associate Professor, UVic Family Physicians Conference February 22, 2012 Victoria,

More information

Jamie A. Micco, PhD APPLYING EXPOSURE AND RESPONSE PREVENTION TO YOUTH WITH PANDAS

Jamie A. Micco, PhD APPLYING EXPOSURE AND RESPONSE PREVENTION TO YOUTH WITH PANDAS APPLYING EXPOSURE AND RESPONSE PREVENTION TO YOUTH WITH PANDAS Jamie A. Micco, PhD Director, Intensive Outpatient Service Child and Adolescent Cognitive Behavioral Therapy Program Massachusetts General

More information

Medical Treatment of Problem Gambling. Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry

Medical Treatment of Problem Gambling. Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry Medical Treatment of Problem Gambling Donald W. Black, M.D. Roy J. and Lucille A. Carver College of Medicine Department of Psychiatry Disclosures Research Support: Forest Labs Nellie Ball Trust Fund National

More information

THE CHALLENGE OF ADHD IN THE PRESCHOOLER

THE CHALLENGE OF ADHD IN THE PRESCHOOLER THE CHALLENGE OF ADHD IN THE PRESCHOOLER Paediatric Refresher Course 2011 Vineyard Hotel Prof A. Venter Department of Paediatrics and Child Health University of the Free State Departement Sentrum Department

More information

Anxiety disorders are remarkably common among pediatric

Anxiety disorders are remarkably common among pediatric Web audio at CurrentPsychiatry.com Dr. Strawn: Predictors of outcome and multimodal treatment for pediatric anxiety An evidence-based approach to treating pediatric anxiety disorders Research supports

More information

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice

More information

The Adolescent with ADHD: Managing Transition

The Adolescent with ADHD: Managing Transition The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli

More information

Obsessive compulsive disorder, tics and anxiety in 6-year-old twins

Obsessive compulsive disorder, tics and anxiety in 6-year-old twins Psychological Medicine, Page 1 of 10. f 2006 Cambridge University Press doi:10.1017/s0033291706008816 Printed in the United Kingdom Obsessive compulsive disorder, tics and anxiety in 6-year-old twins DEREK

More information

Typical or Troubled? Teen Mental Health

Typical or Troubled? Teen Mental Health Typical or Troubled? Teen Mental Health Adolescence is a difficult time for many teens, but how does one know the difference between typical teen issues and behavior that might signal a more serious problem?

More information

FAMILY AND ADOLESCENT MENTAL HEALTH: THE PEDIATRICIAN S ROLE

FAMILY AND ADOLESCENT MENTAL HEALTH: THE PEDIATRICIAN S ROLE FAMILY AND ADOLESCENT MENTAL HEALTH: THE PEDIATRICIAN S ROLE Mark Cavitt, M.D. Medical Director, Pediatric Psychiatry All Children s Hospital/Johns Hopkins Medicine OBJECTIVES Review the prevalence of

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,

More information

11/12/2017. How effective are treatments of psychiatric disorders in children and adolescents?

11/12/2017. How effective are treatments of psychiatric disorders in children and adolescents? How effective are treatments of psychiatric disorders in children and adolescents? Benedetto Vitiello, M.D. Pavia, November 22, 2017 1 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent

More information

Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant

Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island

More information

Drugs, Society and Behavior

Drugs, Society and Behavior SOCI 270 Drugs, Society and Behavior Spring 2016 Professor Kurt Reymers, Ph.D. Chapter 8 Medication for Mental Disorders 1. Mental Disorders: a. The Medical Model Model: symptoms diagnosis determination

More information

Quality of life in children and adolescents with obsessive-compulsive disorder: base rates, parent child agreement, and clinical correlates

Quality of life in children and adolescents with obsessive-compulsive disorder: base rates, parent child agreement, and clinical correlates Soc Psychiat Epidemiol (2009) 44:935 942 DOI 10.1007/s00127-009-0013-9 ORIGINAL PAPER Quality of life in children and adolescents with obsessive-compulsive disorder: base rates, parent child agreement,

More information

Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder

Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants

More information

ORIGINAL RESEARCH Key Words: psychometric evaluation, obsessive-compulsive disorder, co-morbidity, assessment

ORIGINAL RESEARCH Key Words: psychometric evaluation, obsessive-compulsive disorder, co-morbidity, assessment 025-030_PB_V39N1_de_Haan.qxd 9/21/06 5:35 PM Page 25 ORIGINAL RESEARCH Key Words: psychometric evaluation, obsessive-compulsive disorder, co-morbidity, assessment Reliability and Validity of the Yale-Brown

More information

Psychosocial problems in attention-deficit hyperactivity disorder with oppositional defiant disorder

Psychosocial problems in attention-deficit hyperactivity disorder with oppositional defiant disorder Psychiatry and Clinical Neurosciences (2002), 56, 365 369 Regular Article Psychosocial problems in attention-deficit hyperactivity disorder with oppositional defiant disorder YUZURU HARADA, md, phd, 1

More information

Attention-Deficit/Hyperactivity Disorder Nathan J. Blum, M.D.

Attention-Deficit/Hyperactivity Disorder Nathan J. Blum, M.D. ADHD in Preschool Children Preschool ADHD: When Should We Diagnose it & How Should We Treat it? Professor of Pediatrics Diagnosis of ADHD in Preschool Children: Impact of DSM-IV Is Preschool ADHD Associated

More information

A Comparative Study of Socio Demographic and Clinical Profiles in Patient with Obsessive Compulsive Disorder and Depression

A Comparative Study of Socio Demographic and Clinical Profiles in Patient with Obsessive Compulsive Disorder and Depression American Journal of Psychiatry and Neuroscience 2018; 6(4): 99-103 http://www.sciencepublishinggroup.com/j/ajpn doi: 10.11648/j.ajpn.20180604.12 ISSN: 2330-4243 (Print); ISSN: 2330-426X (Online) A Comparative

More information

Illuminating the Black Box: Antidepressants, Youth and Suicide

Illuminating the Black Box: Antidepressants, Youth and Suicide Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry

More information